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n the article by Epstein AE, DiMarco JP, Ellenbogen KA, et al., “ACC/AHA/HRS 2008 Guidelines for Device-Based
herapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association
ask Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for
mplantation of Cardiac Pacemakers and Antiarrhythmia Devices),” which published ahead of print on May 15, 2008, and
ppeared in the May 27, 2008, online issue of the journal (J Am Coll Cardiol 2008;51:e1–e62), the following corrections
ere made:
. On page e17, in the right-hand column, in the first sentence of the first full paragraph, the phrase “or equal to” was
missing and has been added. The text now reads, “The major experience with resynchronization derives from patients
with New York Heart Association (NYHA) Class III symptoms of heart failure and LVEF less than or equal to 35%.”
. On page e21, in Table 2, for “Dual-chamber pacemaker” under the heading “Atrioventricular Block,” there was a
duplication of “Rate Response Available if Desired.” The first instance has been deleted.
. On page e28, in the left-hand column, in the second and third sentences of the second full paragraph, the phrase “or
equal to” was missing and has been added. The text now reads, “The LVEF used in clinical trials assessing the ICD for
primary prevention of SCD ranged from less than or equal to 40% in MUSTT (Multicenter Unsustained Ventricular
Tachycardia Trial) to less than or equal to 30% in MADIT II (Multicenter Automatic Defibrillator Implantation Trial
II) (329,332). Two trials, MADIT I (Multicenter Automatic Defibrillator Implantation Trial I) (327) and SCD-HeFT
(Sudden Cardiac Death in Heart Failure Trial) (333), used LVEFs of less than or equal to 35% as entry criteria.”
. On page e36, in the left-hand column, in the second and third sentences of the fourth full paragraph, the phrase “or equal
to” was missing and has been added. The text now reads, “The LVEF used in clinical trials assessing the ICD for primary
prevention of SCD ranged from less than or equal to 40% in MUSTT to less than or equal to 30% in MADIT II
(329,332). Two trials, MADIT I (18) and SCD-HeFT (19), used LVEFs of less than or equal to 35% as entry criteria
for the trial.”
. On page e36, in the right-hand column, under the Class I heading, the phrase “or equal to” was missing and has been
added to Recommendations 4, 6, and 7. They now read as follows:
4. ICD therapy is indicated in patients with LVEF less than or equal to 35% due to prior MI who are at least 40 days
post-MI and are in NYHA functional Class II or III. (Level of Evidence: A) (16,333)
6. ICD therapy is indicated in patients with LV dysfunction due to prior MI who are at least 40 days post-MI, have an
LVEF less than or equal to 30%, and are in NYHA functional Class I. (Level of Evidence: A) (16,332)
7. ICD therapy is indicated in patients with nonsustained VT due to prior MI, LVEF less than or equal to 40%, and
inducible VF or sustained VT at electrophysiological study. (Level of Evidence: B) (16, 327, 329)
. On page e40, in the right-hand column, in the first sentence of the second full paragraph, the phrase “or equal to” was
missing and has been added. The text now reads, “Among 204 elderly patients with prior MI and LVEF less than or
equal to 30% enrolled in MADIT II (total n1223), a trial of primary prevention of SCD with ICD therapy, the HR
for mortality with ICD therapy was 0.56 (95% CI 0.29 to 1.08; p0.08), which was similar to that for younger patients
(HR 0.63, 95% CI 0.45 to 0.88; p0.01) (482a).”
To access the most current online version of the article, visit http://content.onlinejacc.org/cgi/content/full/51/21/e1.
doi:10.1016/j.jacc.2008.10.006
n the executive summary of the article by Epstein AE, DiMarco JP, Ellenbogen KA, et al., “ACC/AHA/HRS 2008
uidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of
ardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/
HA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices),” which
ublished ahead of print on May 15, 2008, and appeared in the May 27, 2008, issue of the journal (J Am Coll Cardiol
008;51:2085–105), the following corrections should be made:
. On page 2090, in Table 2, for “Dual-chamber pacemaker” under the heading “Atrioventricular Block,” there is a
duplication of “Rate Response Available if Desired.” The first instance should be deleted.
. On page 2096, in the left-hand column, in the second and third sentences of the first full paragraph, the phrase “or equal
to” is missing and should be added. The text should read, “The LVEF used in clinical trials assessing the ICD for primary
prevention of SCD ranged from less than or equal to 40% in MUSTT (Multicenter Unsustained Ventricular Tachycardia
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December 30/January 6, 2009:147–8Trial) to less than or equal to 30% in MADIT II (Multicenter Automatic Defibrillator Implantation Trial II) (131,132).
Two trials, MADIT I (Multicenter Automatic Defibrillator Implantation Trial I) (6) and SCD-HeFT (Sudden Cardiac
Death in Heart Failure Trial) (7), used LVEFs of less than or equal to 35% as entry criteria.”
. On page 2096, in the left-hand column, under the Class I heading, the phrase “or equal to” is missing and should be
added to Recommendations 4, 6, and 7. They should read as follows:
4. ICD therapy is indicated in patients with LVEF less than or equal to 35% due to prior myocardial infarction who are
at least 40 days post-myocardial infarction and are in NYHA functional Class II or III. (Level of Evidence: A) (4,139)
6. ICD therapy is indicated in patients with LV dysfunction due to prior myocardial infarction who are at least 40 days
post-myocardial infarction, have an LVEF less than or equal to 30%, and are in NYHA functional Class I. (Level of
Evidence: A) (4,132)
7. ICD therapy is indicated in patients with nonsustained VT due to prior myocardial infarction, LVEF less than or equal
to 40%, and inducible ventricular fibrillation or sustained VT at electrophysiological study. (Level of Evidence: B)
(4,131,142)
doi:10.1016/j.jacc.2008.10.007
